ABCC7 p.Lys370*
[switch to full view]Comments [show]
None has been submitted yet.
PMID: 9813087
[PubMed]
Jiang Q et al: "Cystic fibrosis transmembrane conductance regulator-associated ATP release is controlled by a chloride sensor."
No.
Sentence
Comment
92
The COOH-terminal truncation mutant, TMD1 CFTR, was constructed by introducing a stop codon at K370X followed by an EcoRV restriction site using the mutagenic oligonucleotide 5Ј-GCAATAAACTAAATACAG- GATATCTTAC-3Ј.
X
ABCC7 p.Lys370* 9813087:92:95
status: NEW
PMID: 9482946
[PubMed]
Schwiebert EM et al: "Chloride channel and chloride conductance regulator domains of CFTR, the cystic fibrosis transmembrane conductance regulator."
No.
Sentence
Comment
172
More importantly, results with T-N-R CFTR suggest that the region of CFTR important for regulatory interaction with ORCCs lies Table 2. cAMP-stimulated Cl- efflux in CFTR cDNA-transfected IB3-1 CF cells cDNA transfected n Cl- efflux, % lost per min Paired P valueBefore agonists After agonists Mock 42 33.01 Ϯ 3.12 29.53 Ϯ 2.22 NS Wild-type 37 22.99 Ϯ 1.47 46.51 Ϯ 6.53* Ͻ0.005 ⌬259-M265 30 21.85 Ϯ 1.43 47.67 Ϯ 5.95* Ͻ0.005 ⌬259-M265V 18 24.55 Ϯ 1.17 29.25 Ϯ 2.23** Ͻ0.05 TMD-1 (K370X) 24 16.63 Ϯ 1.80 53.51 Ϯ 9.50* Ͻ0.005 TMD-1 (K370EcoRV) 24 19.54 Ϯ 1.67 41.27 Ϯ 5.22* Ͻ0.005 T-N-R 18 19.21 Ϯ 1.89 28.05 Ϯ 3.35** Ͻ0.05 R334W-R347P 18 19.85 Ϯ 3.20 31.16 Ϯ 6.79** Ͻ0.05 R334W-R347P-TMD-1 18 23.12 Ϯ 2.60 26.26 Ϯ 3.42 NS The Before agonists value is the rate of 36Cl- efflux immediately prior to stimulation with cAMP agonists (2.5 M forskolin, 250 M CPT-cAMP, and 250 M 8-bromo-cAMP).
X
ABCC7 p.Lys370* 9482946:172:560
status: NEW174 For mutants ⌬259-M265V, T-N-R, and R334W-R347P, the magnitude of cAMP stimulation is significantly less (P Ͻ 0.05, versus paired control value as denoted by two asterisks) than that for the wild type and other responding mutants [⌬259-M265, TMD-1 (K370X), TMD-1 (K370EcoRV), P Ͻ 0.005 as denoted by one asterisk], as determined by ANOVA followed by the Bonferroni ad hoc test.
X
ABCC7 p.Lys370* 9482946:174:268
status: NEW171 More importantly, results with T-N-R CFTR suggest that the region of CFTR important for regulatory interaction with ORCCs lies Table 2. cAMP-stimulated Cl2 efflux in CFTR cDNA-transfected IB3-1 CF cells cDNA transfected n Cl2 efflux, % lost per min Paired P value Before agonists After agonists Mock 42 33.01 6 3.12 29.53 6 2.22 NS Wild-type 37 22.99 6 1.47 46.51 6 6.53* ,0.005 D259-M265 30 21.85 6 1.43 47.67 6 5.95* ,0.005 D259-M265V 18 24.55 6 1.17 29.25 6 2.23** ,0.05 TMD-1 (K370X) 24 16.63 6 1.80 53.51 6 9.50* ,0.005 TMD-1 (K370EcoRV) 24 19.54 6 1.67 41.27 6 5.22* ,0.005 T-N-R 18 19.21 6 1.89 28.05 6 3.35** ,0.05 R334W-R347P 18 19.85 6 3.20 31.16 6 6.79** ,0.05 R334W-R347P-TMD-1 18 23.12 6 2.60 26.26 6 3.42 NS The Before agonists value is the rate of 36Cl2 efflux immediately prior to stimulation with cAMP agonists (2.5 mM forskolin, 250 mM CPT-cAMP, and 250 mM 8-bromo-cAMP).
X
ABCC7 p.Lys370* 9482946:171:481
status: NEW173 For mutants D259-M265V, T-N-R, and R334W-R347P, the magnitude of cAMP stimulation is significantly less (P , 0.05, versus paired control value as denoted by two asterisks) than that for the wild type and other responding mutants [D259-M265, TMD-1 (K370X), TMD-1 (K370EcoRV), P , 0.005 as denoted by one asterisk], as determined by ANOVA followed by the Bonferroni ad hoc test.
X
ABCC7 p.Lys370* 9482946:173:248
status: NEW
PMID: 9374850
[PubMed]
McNicholas CM et al: "A functional CFTR-NBF1 is required for ROMK2-CFTR interaction."
No.
Sentence
Comment
14
However, in oocytes coinjected with ROMK2 and a CFTR mutant truncated immediately before NBF1 (CFTR-K370X), glibenclamide inhibited Kϩ currents by 12%.
X
ABCC7 p.Lys370* 9374850:14:100
status: NEW69 The oligonucleotides used for mutagenesis were CFTR-G551D:5Ј GAGTGGAGAT- CAACGAG 3Ј, CFTR-A455E:5Ј GTTGTTGGAGGTTGCTGG 3Ј, CFTR-K370X:5Ј GCAATAAACTAAATACAGGATATCTTAC 3Ј, and CFTR-K593X:5Ј CTGTTAACTGATGGCTAGCAAACTAGG 3Ј.
X
ABCC7 p.Lys370* 9374850:69:151
status: NEW84 To test our hypothesis, we measured the glibenclamide sensitivity of the Kϩ currents (using the experimental protocol described above) when ROMK2 was coexpressed with two engineered CFTR-mutant constructs, CFTR-K593X or CFTR-K370X, or two naturally occurring CFTR-mutant constructs, CFTR-G551D or CFTR-A455E (see Fig. 2).
X
ABCC7 p.Lys370* 9374850:84:231
status: NEW87 In our initial experiments with the mutant CFTR constructs, we coexpressed ROMK2 with either CFTR truncated after NBF1 (CFTR-K593X, Fig. 2) or CFTR truncated before NBF1 (CFTR-K370X, Fig. 2).
X
ABCC7 p.Lys370* 9374850:87:176
status: NEW92 Therefore, the mutant CFTR-K593X is similar to CFTR-WT in conferring glibenclamide sensitivity on ROMK2.
X
ABCC7 p.Lys370* 9374850:92:140
status: NEW97 C: CFTR-K370X is truncated at residue 370 prior to NBF1.
X
ABCC7 p.Lys370* 9374850:97:8
status: NEW100 To examine whether CFTR-NBF1 is the important region for this interaction and not the transmembrane domains, we coexpressed ROMK2 with CFTR-K370X (Fig. 2).
X
ABCC7 p.Lys370* 9374850:100:140
status: NEW102 When ROMK2 and CFTR-K370X were coexpressed, the observed Ba2ϩ- sensitive Kϩ currents decreased by only 12.3 Ϯ 3.3% (n ϭ 12) after oocytes were exposed to glibenclamide.
X
ABCC7 p.Lys370* 9374850:102:20
status: NEWX
ABCC7 p.Lys370* 9374850:102:172
status: NEW110 Sensitivity of CFTR Cl- currents to glibenclamide Construct Whole Cell Current, nA %Inhibition By Glibenclamide n P CFTR-WT 560Ϯ150 51.9 9 CFTR-K593X 190Ϯ31 50.1 8 NS CFTR-K370X 183Ϯ85 44.1 5 NS CFTR-G551D 334Ϯ80 49.6 7 NS CFTR-A455E 299Ϯ27 63.2 5 NS Uninjected 26Ϯ10 0 5 0.02 Values are means Ϯ SE; n is no. of experiments.
X
ABCC7 p.Lys370* 9374850:110:184
status: NEW8 However, in oocytes coinjected with ROMK2 and a CFTR mutant truncated immediately before NBF1 (CFTR-K370X), glibenclamide inhibited K1 currents by 12%.
X
ABCC7 p.Lys370* 9374850:8:100
status: NEW62 The oligonucleotides used for mutagenesis were CFTR-G551D:58 GAGTGGAGAT- CAACGAG 38, CFTR-A455E:58 GTTGTTGGAGGTTGCTGG 38, CFTR-K370X:58 GCAATAAACTAAATACAGGATATCTTAC 38, and CFTR-K593X:58 CTGTTAACTGATGGCTAGCAAACTAGG 38.
X
ABCC7 p.Lys370* 9374850:62:127
status: NEW77 To test our hypothesis, we measured the glibenclamide sensitivity of the K1 currents (using the experimental protocol described above) when ROMK2 was coexpressed with two engineered CFTR-mutant constructs, CFTR-K593X or CFTR-K370X, or two naturally occurring CFTR-mutant constructs, CFTR-G551D or CFTR-A455E (see Fig. 2).
X
ABCC7 p.Lys370* 9374850:77:225
status: NEW80 In our initial experiments with the mutant CFTR constructs, we coexpressed ROMK2 with either CFTR truncated after NBF1 (CFTR-K593X, Fig. 2) or CFTR truncated before NBF1 (CFTR-K370X, Fig. 2).
X
ABCC7 p.Lys370* 9374850:80:176
status: NEW89 C: CFTR-K370X is truncated at residue 370 prior to NBF1.
X
ABCC7 p.Lys370* 9374850:89:8
status: NEW94 When ROMK2 and CFTR-K370X were coexpressed, the observed Ba21-sensitive K1 currents decreased by only 12.3 6 3.3% (n 5 12) after oocytes were exposed to glibenclamide.
X
ABCC7 p.Lys370* 9374850:94:20
status: NEW